MAJ'STEROL
Food supplement declared in France, declaration No 2024-2-1121, decision dated 19 February 2024
MAJ'STEROL (MAJELIS) is a food supplement declared in France. Status: declared in France, may be marketed. 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- MAJELIS
- Food business operator placing the product on the market
- SAS MAJELIS
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 1 gélule
- Directions for use
- 1 gélule par jour
- Intended populations
- Men, Women
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Pregnant women, Taking medication
- Objectives stated by the manufacturer (these are not authorised claims)
- Arteries and cholesterol
Declaration 139156, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Monascus purpureus Went | Graine | Poudre (de plantes séchées ou broyées) | 140 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Fibres de pomme | not declared |
| Ubiquinone | not declared |
Additives
Hydroxypropyl Méthyl Cellulose
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Ne doit pas être consommé par les femmes enceintes ou allaitantes, les enfants de moins de 18 ans et les adultes de plus de 70 ans. Demandez conseil à un médecin sur la consommation de ce produit en cas de problèmes de santé. Ne doit pas être consommé en cas de prise de médicaments pour réduire le cholestérol. Ne doit pas être consommé si vous consommez déjà d’autres produits contenant de la levure rouge de riz (ne pas consommer journalièrement 3 mg ou plus de monacolines). Déconseillé aux personnes sensibles aux statines.
Regulatory points
- Conditions légales
Contains red yeast rice. Monacolins must remain below 3 mg per daily portion, with mandatory warnings on the label. The monacolin content is not declared in Compl'Alim.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/860).
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Ubiquinone
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : MAJELIS
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.